BMS-275291. Bristol-Myers Squibb.

Abstract

Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential treatment of cancer. It was originally developed by Chiroscience R&D (now known as Celltech Group plc), and it inhibits a broad range of MMPs known to be associated with the growth and spread of tumors. Advantageously, it does not inhibit MMP-mediated shedding events, which may be involved in the side effects associated withfirst-generation MMP inhibitors. ByMarch 2001, BMS-275291 was undergoing phase II/III trials, as an adjunct to standard chemotherapy, involving non-small cell lung cancer patients. In March 1999, Lehman Brothers predicted that the compound had a 25% chance of reaching the market, with a possible launch anticipated in 2005 and potential peak sales of $500 million in 2010. In November 2000, Lehman Brothers revised their predictions estimating a 2004 launch with a 20% chance of reaching the market; predicted peak sales were unchanged. In January 2002, Morgan Stanley Dean Witter expressed the view that release of positive phase II/III trials data would surprise stock markets.

• Authors: Vassiliki Poulaki
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 3 Pg. 500-4 (Mar 2002) ISSN: 1472-4472 [Print] England
• PMID: 12054103 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Enzyme Inhibitors
• Imidazoles
• Matrix Metalloproteinase Inhibitors
• Organic Chemicals
• N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide

Topics

• Animals
• Antineoplastic Agents (adverse effects, chemical synthesis, metabolism, pharmacology, therapeutic use, toxicity)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Contraindications
• Enzyme Inhibitors (adverse effects, chemical synthesis, metabolism, pharmacology, therapeutic use, toxicity)
• Humans
• Imidazoles
• Matrix Metalloproteinase Inhibitors
• Neoplasms (drug therapy)
• Organic Chemicals
• Structure-Activity Relationship